First New Drug for Liver Cancer in a Decade: Regorafenib

The US Food and Drug Administration (FDA) has expanded the indication for regorafenib (Stivarga, Bayer) to now include treatment for patients with hepatocellular carcinoma (HCC) who have previously been treated with the drug sorafenib (Nexavar, Bayer).

Expansion of regorafenib's indication marks the first FDA-approved treatment for a liver cancer in almost a decade!

Medscape article: http://www.medscape.com/viewarticle/879216?src=soc_fb_170427_mscpedt_news_onc_livercancer